logo
Scientists Discover a Simple Set of Rules That May Explain How Our Tissues Stay Organized

Scientists Discover a Simple Set of Rules That May Explain How Our Tissues Stay Organized

Business Wire7 hours ago
WILMINGTON, Del.--(BUSINESS WIRE)--Every day, your body replaces billions of cells—and yet, your tissues stay perfectly organized. How is that possible?
'Just like we have a genetic code that explains how our genes work, we may also have a 'tissue code' that explains how our bodies stay so precisely organized over time,' said Bruce Boman, M.D., Ph.D.
Share
A team of researchers at ChristianaCare's Helen F. Graham Cancer Center & Research Institute and the University of Delaware believe they've found an answer. In a new study published today in the scientific journal Biology of the Cell, they show that just five basic rules may explain how the body maintains the complex structure of tissues like those in the colon, for example, even as its cells are constantly dying and being replaced.
Download photos.
This research is the product of more than 15 years of collaboration between mathematicians and cancer biologists to unlock the rules that govern tissue structure and cellular behavior.
'This may be the biological version of a blueprint,' said Bruce Boman, M.D., Ph.D., senior research scientist at ChristianaCare's Cawley Center for Translational Cancer Research and faculty member in the departments of Biological Sciences and Mathematical Sciences at the University of Delaware. 'Just like we have a genetic code that explains how our genes work, we may also have a 'tissue code' that explains how our bodies stay so precisely organized over time.'
Math Meets Medicine
The researchers used mathematical modeling—essentially, creating a computer simulation of how cells behave—to see if a small number of rules could account for the highly organized structure of the lining of the colon. That's an ideal place to study: cells in the colon renew every few days, but the overall shape and structure stays remarkably stable.
After running many simulations and refining their models, the team identified five core biological rules that appear to govern the structure and behavior of cells:
Timing of cell division.
The order in which cells divide.
The direction cells divide and move.
How many times cells divide.
How long a cell lives before it dies.
'These rules work together like choreography,' said Gilberto Schleiniger, Ph.D., professor in the University of Delaware's Department of Mathematical Sciences. 'They control where cells go, when they divide and how long they stick around—and that's what keeps tissues looking and working the way they should.'
Decoding Human Tissue
The researchers believe these rules may apply not just to the colon, but to many different tissues throughout the body—skin, liver, brain and beyond. If true, this 'tissue code' could help scientists better understand how tissues heal after injury, how birth defects happen and how diseases like cancer develop when that code gets disrupted.
Boman explained it this way: 'Your tissues don't just grow and shrink randomly. They know what they're supposed to look like, and they know how to get back to that state, even after damage. That level of precision needs a set of instructions. What we've found is a strong candidate for those instructions.'
This work also has important implications for the Human Cell Atlas, a global scientific collaboration working to map every cell type in the human body. While the Atlas aims to catalog what each cell is and what it's doing at a given moment, this new research offers a dynamic framework for understanding how those cells stay organized over time. By identifying simple, universal rules that govern cell behavior and tissue structure, the findings could help guide future efforts to not only describe cells, but predict how they behave in health and disease.
Implications for Disease and Discovery
One reason the team turned to mathematical models, rather than traditional biology experiments, is that it's extremely difficult to observe how every single cell in a tissue behaves in real time. But with computer models, researchers can run simulations that reveal patterns and dynamics hidden from view.
This kind of collaboration between biology and math reflects a broader shift in how scientists approach complex problems. It also aligns with national priorities: the National Science Foundation's ' Rules of Life ' initiative challenges researchers to uncover the fundamental principles that govern living systems. This study is a strong step in that direction.
Next steps for the team include testing the model's predictions experimentally, refining it with additional data and exploring its relevance to cancer biology—especially how disruptions to the tissue code may lead to tumor growth or metastasis.
'This is just the beginning,' said Schleiniger. 'Once you can identify the rules, you can begin to ask entirely new questions, and maybe even learn how to fix what's gone wrong.'
Funding for this project was provided by the National Institutes of Health, the National Science Foundation, The Lisa Dean Moseley Foundation, the Delaware Bioscience Center for Advanced Technology (CAT) and the UNIDEL Graduate Research Fellowship.
About ChristianaCare
Headquartered in Wilmington, Delaware, ChristianaCare is one of the country's most dynamic health care organizations, centered on improving health outcomes, and innovating to make high-quality care more accessible, equitable and affordable. ChristianaCare includes an extensive network of primary care and outpatient services, home health care, urgent care centers, three hospitals (1,430 beds), a freestanding emergency department, a Level I trauma center and a Level III neonatal intensive care unit, a comprehensive stroke center and regional centers of excellence in heart and vascular care, cancer care and women's health. It also includes the pioneering Gene Editing Institute.
ChristianaCare is nationally recognized as a great place to work, rated by Forbes as one of the nation's best employers for diversity and inclusion. ChristianaCare is rated by Newsweek as one of the World's Best Hospitals and is continually ranked among the best in the U.S. in national quality and safety ratings. ChristianaCare is a nonprofit teaching health system with more than 260 residents and fellows. With its groundbreaking Center for Virtual Health and a focus on population health and value-based care, ChristianaCare is shaping the future of health care.
About the Cawley Center for Translational Cancer Research
The Cawley Center for Translational Cancer Research (CTCR) at the Helen F. Graham Cancer Center & Research Institute moves research from the laboratory bench to the patient's bedside by applying basic science toward potential therapies. The Cawley CTCR is where scientists study the molecular causes of cancer and tissue engineering, all targeted to better treatment for patients. Groundbreaking findings and current studies at the center are helping to prevent, better detect and stop the growth of many cancers — and as a result reducing cancer incidence and mortality rates in Delaware and beyond.
About the University of Delaware
The University of Delaware traces its roots to 1743, making it the seventh-oldest higher education institution in the country. UD's tradition of excellence continues today in both the classroom and the laboratory, with consistent ranking among the top 40 public universities. Beyond its Georgian-inspired main campus in Newark, Delaware, UD has locations in Wilmington, Dover, Georgetown and Lewes, in addition to a growing online learning environment.
UD is a state-assisted, privately governed institution and one of a select group to hold the triple Land Grant, Sea Grant and Space Grant designation. UD is classified nationally as a Research 1 (R1) university for its very high research activity and doctorate production, a designation held by less than 5% of U.S. colleges and universities. UD also is recognized as a Community Engaged University for its long tradition of applying knowledge and creativity to the critical challenges facing communities in Delaware and around the world.
About the University of Delaware's Department of Mathematical Sciences
The University of Delaware's Department of Mathematical Sciences offers a diverse suite of programs – from actuarial science and applied mathematics to mathematics‑and‑economics, mathematics education, and quantitative biology – designed to develop both deep theoretical insight and practical problem-solving skills. The department's vibrant community of scholars and educators is anchored by the Mathematical Sciences Learning Lab and the Center for Applications of Mathematics in Medicine. Faculty and students collaborate on cutting‑edge research across pure and applied mathematics – exploring topics such as algebra, topology, probability, and graph theory – and join forces with colleagues in computer science, data science, engineering, biology, and neuroscience.
About the University of Delaware's Department of Biological Sciences
The Department of Biological Sciences at the University of Delaware is a dynamic and interdisciplinary community of scholars, researchers, and educators. With a proud legacy of academic excellence and a strong track record of external research funding, the department offers an exceptional undergraduate experience that blends classroom instruction, problem-based learning, hands-on lab training, and mentored research in faculty labs. This comprehensive approach equips students with the skills and knowledge to thrive in a wide range of careers or advanced studies. At the graduate level, the department focuses on uncovering the molecular mechanisms of life, using bacterial, invertebrate, and vertebrate model systems to advance understanding and improve human health and society. Our collaborative teaching and research environment spans molecular biology and genetics, developmental biology, cell and tissue physiology, microbiology, and science education – creating a vibrant, inclusive, and impactful scientific community.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Elucid Applauds CMS Inclusion of Coronary CTA with Plaque Analysis in 2026 Proposed Medicare Physician Fee Schedule
Elucid Applauds CMS Inclusion of Coronary CTA with Plaque Analysis in 2026 Proposed Medicare Physician Fee Schedule

Business Wire

time24 minutes ago

  • Business Wire

Elucid Applauds CMS Inclusion of Coronary CTA with Plaque Analysis in 2026 Proposed Medicare Physician Fee Schedule

BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, today released a statement commending U.S. Centers for Medicare & Medicaid Services (CMS) for the inclusion of a Category I CPT code for coronary plaque analysis and a national Medicare average payment amount of over $1,000, pending the final Medicare Physician Fee Schedule (PFS) ruling, which will come out in November. 'Elucid is encouraged by the addition of the Category I CPT code and payment level for coronary CTA with plaque analysis in the Calendar Year 2026 Medicare Physician Fee Schedule proposed rule,' said Elucid CEO Kelly Huang, PhD. Cardiovascular disease continues to be a critical public health issue in the United States, remaining the leading cause of death nationwide. In 2022, heart disease claimed over 700,000 lives—nearly 1 in every 5 deaths—underscoring the urgent need for early detection and intervention. 1 Despite advances, many high‑risk patients remain undiagnosed until they experience serious cardiac events. The proposed rule by CMS marks a significant step toward broader access to innovative, evidence-based imaging tools that help identify high-risk cardiovascular patients earlier and more accurately. 'Elucid is encouraged by the addition of the Category I CPT code and payment level for coronary CTA with plaque analysis in the Calendar Year 2026 Medicare Physician Fee Schedule proposed rule,' said Elucid CEO Kelly Huang, PhD. 'We commend CMS for ensuring that the proposed payment level reflects the clinical value, technological investment, and expertise needed to perform this service, enabling Medicare beneficiaries to access this technology.' Coronary computed tomography angiography (CTA) with plaque analysis offers invaluable insights into plaque burden, composition, and morphology, enabling earlier and more accurate identification of high-risk patients who may benefit from targeted medical therapy and lifestyle interventions. Numerous studies have demonstrated that such non-invasive imaging enhances risk stratification and clinical decision-making while reducing the need for more invasive and costly diagnostic procedures. 'Elucid remains optimistic as we await the final publication of the code and payment, effective January 1, 2026,' said Huang. 'We recognize the efforts of societies and physician organizations collaborating with the AMA and CMS to reach an appropriate payment level. We look forward to continued cooperation to enhance patient outcomes and access.' The proposed rule outlines payment policies and rates for services furnished under Medicare Part B. The inclusion of coronary CTA with plaque analysis represents a significant advancement for precision cardiovascular care. It follows a new CMS rule that went into effect January 1, 2025, which doubled the amount paid to hospitals and outpatient clinics who perform cardiac CT scans from $175 to $357. This has already allowed more hospitals, particularly those in non-urban areas, to be able to offer this service, reducing disparities in care. About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit

Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division

Business Wire

time38 minutes ago

  • Business Wire

Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division

MATAWAN, N.J.--(BUSINESS WIRE)--Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) ('Apimeds' or the 'Company'), a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered, bee venom-based therapeutic, today announced two key additions to its executive leadership team. Susan Kramer, DrPH, has been appointed Senior Vice President of Development, and Brian Peters has joined as Head of the Company's proprietary ai²™ division. Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division Dr. Kramer brings more than 30 years of experience in biopharmaceutical research and development, including 18 years at Genentech. She most recently served as Executive Vice President of Development at Concentric Analgesics. Mr. Peters, previously Chief Strategy & Insights Officer at Heller Agency, has a proven track record in healthcare innovation, strategic communications, and KOL engagement. In their new roles, Dr. Kramer will oversee all product development activities at Apimeds, while Mr. Peters will lead the strategy, positioning, and launch of the Company's ai²™ platform. 'We're thrilled to welcome Susan and Brian to the Apimeds leadership team,' said Erik Emerson, Chief Executive Officer of Apimeds. 'Strengthening our operational leadership has been a priority since our IPO. Susan enhances our clinical development capabilities at a pivotal time for Apitox, while Brian brings vision, energy, and deep strategic expertise as we build and scale our ai²™ platform.' ' Apitox is an incredibly exciting program,' said Dr. Kramer. 'Having worked with Erik in the past, I know the caliber of his leadership. The scientific potential of purified bee venom and the company's mission made this an easy decision. I'm eager to explore the range of indications where Apitox may bring meaningful therapeutic benefits.' 'Joining Apimeds at this inflection point is an amazing opportunity,' added Mr. Peters. 'The chance to shape and launch ai²™—our internal innovation engine—is compelling in its own right, but combining it with a pipeline as novel as Apitox makes this a truly unique moment.' Dr. Kramer is a co-founder of Corthera, Inc. (acquired by Novartis), and has held senior roles at XOMA, Anesiva, and Annexon Biosciences. She has led global development teams for both biologics and small molecules. She holds a BA from the College of St. Scholastica, an MA in Education from Central Michigan University, and both an MPH and DrPH in Biomedical Sciences (Virology) from the University of California, Berkeley. She has served on numerous boards and scientific advisory committees. Mr. Peters previously served as VP of Sales & Marketing and as a member of the corporate leadership team at Medexus Pharma from 2013 to 2024. Earlier in his career, he held senior leadership positions at Gilead Sciences, Accera, Chiesi, and G.D. Searle. He earned a BA in Communications from Indiana University. About Apimeds Pharmaceuticals US, Inc. Apimeds is a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered honeybee venom-based toxin. Apimeds is currently developing Apitox as a potential treatment for osteoarthritis knee pain in patients who fail to respond adequately to conservative non-pharmacologic therapy and common analgesics. For more information, please visit Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated use of the net proceeds from the offering. No assurance can be given that the net proceeds of the Offering will be used as indicated. All statements other than statements of historical facts are forward-looking statements. You can identify these forward-looking statements by words or phrases such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'likely to' or other similar expressions. The Company has based these forward-looking statements largely on its current expectations and projections about future events that it believes may affect its financial condition, results of operations, business strategy and financial needs. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These risks and uncertainties include forward-looking statements include, but are not limited to, the risks and uncertainties described in 'Special Note Regarding Forward-Looking Statements,' 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' and the documents that referred to in the prospectus filed with the SEC with the understanding that the Company's future results may be materially different from and worse than what we expect. Copies are available on the SEC's website, Other sections of the prospectus include additional factors which could adversely impact the Company's business and financial performance. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for the Company's management to predict all risk factors and uncertainties, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. The Company and the underwriters qualify all of the forward-looking statements by these cautionary statements. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in the prospectus relate only to events or information as of the date on which the statements are made in the prospectus. Neither the Company nor the underwriters undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read the prospectus and the documents that we refer to in the prospectus and have filed as exhibits to the registration statement, of which the prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect.

BerryDunn Elevates Services for Critical Access Hospitals Nationwide
BerryDunn Elevates Services for Critical Access Hospitals Nationwide

Business Wire

time43 minutes ago

  • Business Wire

BerryDunn Elevates Services for Critical Access Hospitals Nationwide

PORTLAND, Maine--(BUSINESS WIRE)--BerryDunn, a full-service accounting, tax, and consulting firm, has elevated its broad range of professional services tailored to Critical Access Hospitals (CAHs) across the country. The firm helps CAHs respond to today's significant challenges, from funding uncertainties to rapidly evolving technology concerns such as cybersecurity, AI, and aging Electronic Health Record (EHR) systems. 'Our depth of experience in this field goes back nearly 30 years to when BerryDunn began partnering with the very first hospital to earn Critical Access Hospital certification,' says Denny Roberge, Principal and Revenue Cycle Lead. 'Today, as hospitals face mounting financial pressures, including recent cuts to Medicaid funding, we remain 100% committed to supporting the financial health of CAHs and preserving their indispensable role as safety nets in rural communities.' A trusted partner to a growing number of CAHs around the country, BerryDunn collaborates closely with healthcare providers to understand their challenges from every angle. The firm's breadth of specialized services for CAHs spans reimbursement consulting, revenue cycle support and optimization, compliance and credentialing services, technology consulting, financial statement audits, and other services to help CAHs minimize risk, maximize opportunities, and optimize their operations. Many CAHs are coping with aging technology that leaves them vulnerable to a variety of business continuity risks. BerryDunn is experienced in helping clients assess cybersecurity vulnerabilities and better defend against data breaches and cyberattacks. The firm plays a key role in the evaluation and selection of new EHR systems, providing comprehensive implementation support and project management services. 'Our teams bring a high level of specialized knowledge to CAHs confronted by a wide range of tech-related issues,' says Dan Vogt, Principal and Healthcare Technology Consultant. 'Clients struggling with outdated legacy EHR systems rely on our team to guide the transition to a new integrated, automated electronic system, enabling them to stay technologically viable.' As CAHs face escalating financial uncertainties, BerryDunn teams focus on helping them do more with less. With an expanding geographic footprint and an ever-broadening range of services, BerryDunn is helping CAHs improve their financial stability, comply with evolving regulations, tighten cybersecurity protections, and facilitate positive outcomes for their patients. About BerryDunn BerryDunn is the brand name under which Berry, Dunn, McNeil & Parker, LLC and BDMP Assurance, LLP, independently owned entities, provide services. Since 1974, BerryDunn has helped businesses, nonprofits, and government agencies throughout the US and its territories solve their greatest challenges. The firm's tax, advisory, and consulting services are provided by Berry, Dunn, McNeil & Parker, LLC, and its attest services are provided by BDMP Assurance, LLP, a licensed CPA firm. BerryDunn is a client-centered, people-first professional services firm with a mission to empower the meaningful growth of our people, clients, and communities. Led by CEO Sarah Belliveau, the firm has been recognized for its efforts in creating a diverse and inclusive workplace culture, and for its focus on learning, development, and well-being. Learn more at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store